Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Beats Estimates By $0.06 EPS

by · The Markets Daily

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports.

Compass Therapeutics Trading Up 0.8%

Shares of Compass Therapeutics stock traded up $0.03 during trading on Wednesday, reaching $3.82. The company’s stock had a trading volume of 2,893,363 shares, compared to its average volume of 1,451,090. The firm has a market cap of $528.24 million, a PE ratio of -8.49 and a beta of 1.48. Compass Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $4.86. The company has a 50-day moving average price of $3.74 and a two-hundred day moving average price of $2.94.

Analyst Ratings Changes

Several research firms have recently commented on CMPX. Lifesci Capital initiated coverage on shares of Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target for the company. D. Boral Capital reissued a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research report on Wednesday. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim upped their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Check Out Our Latest Stock Report on CMPX

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CMPX. Strs Ohio purchased a new stake in shares of Compass Therapeutics in the 1st quarter worth about $34,000. Creative Planning acquired a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $30,000. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $84,000. Invesco Ltd. increased its position in Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after purchasing an additional 21,578 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Featured Stories